Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study

BACKGROUND: The second-generation ALK inhibitor alectinib recently demonstrated superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), establishing alectinib as the new standard first-lin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Thorac Oncol
Auteurs principaux: Lin, Jessica J., Zhu, Viola W., Schoenfeld, Adam J., Yeap, Beow Y., Saxena, Ashish, Ferris, Lorin A., Dagogo-Jack, Ibiayi, Farago, Anna F., Taber, Angela, Traynor, Anne, Menon, Smitha, Gainor, Justin F., Lennerz, Jochen K., Plodkowski, Andrew J., Digumarthy, Subba R., Ou, Sai-Hong Ignatius, Shaw, Alice T., Riely, Gregory J.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6341982/
https://ncbi.nlm.nih.gov/pubmed/29935304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.06.005
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires